Target intelligence / Profile preview

DNA topoisomerase 3-beta-1 (TOP3B)

Target
TOP3B
Molecular classification
Enzyme, Type IA topoisomerase
01

Overview

DNA topoisomerase 3-beta-1 (TOP3B) is a unique metazoan enzyme in the type IA family, notable for its ability to act on both DNA and RNA substrates. It resolves DNA/RNA topological entanglements—unknotting, decatenating, and resolving supercoils—by transiently breaking and rejoining single-stranded DNA or RNA, permitting the passage of another strand. Unlike most topoisomerases, TOP3B also participates robustly in RNA metabolism, including the disassembly of R-loops, regulation of mRNA translation, and association with the scaffold protein TDRD3 (which recruits TOP3B to specific chromatin or RNA sites). Its physiological importance in genome stability, neurodevelopment, and aging is well established. Mutations in TOP3B are linked to neurodevelopmental disorders, and its diverse nucleic acid substrate recognition makes it an emerging target for antiviral and anticancer drug discovery.

Other names
DNA topoisomerase III betaTOP3BTOP3B1topoisomerase (DNA) III betaDNA topoisomerase 3-beta-1DNA topoisomerase III beta-1topoisomerase III beta
02

Mechanism of action

For theoretical/topoisomerase-directed small molecules: Inhibition of TOP3B would block relaxation of DNA/RNA structures, increase accumulation of R-loops and/or DNA damage, leading to cytostatic or cytotoxic effects (extrapolated from general topoisomerase mechanisms)

03

Biological functions

Solving DNA and RNA topological problems (e.g., decatenation, unknotting, relaxation of supercoils)R-loop disassembly (resolution of DNA/RNA hybrid structures)Regulation of mRNA translationGenome stability maintenanceNeurodevelopment and neuronal function
04

Disease associations

Neurodevelopmental disorders and intellectual disability (mutations linked to neurological disease)Cancer (considered a potential anticancer drug target)Viral infection/antiviral mechanisms (emerging evidence as a drug target)
05

Safety considerations

Targeting TOP3B may pose risks of genome instability and neurodevelopmental toxicity, given its essential roles in neural development and regulation of mRNA translationPotential for off-target effects impacting both DNA and RNA metabolism
06

Biomarkers

Currently none established or validated specifically for TOP3B in clinical use

Beyond the preview

Go deeper on DNA topoisomerase 3-beta-1 (TOP3B).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on DNA topoisomerase 3-beta-1 (TOP3B).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call